May 13, 2024 – Page 11 – Goldea Capital

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million – – Ended the quarter with $350.3 million of cash, cash equivalents and investments, providing cash runway into 2027 – NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory...

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “During the first quarter we advanced our clinical pipeline, most recently marked...

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. “Our review of strategic options continues, as we strive to maximize value for our stockholders,” said Mel Sorensen, M.D., Galera’s President and CEO. “Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path for avasopasem. The process...

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half of 2024 Randomization in PRAX-562 Phase 2 EMBOLD study completed in pediatric patients with developmental and epileptic encephalopathies (DEEs), with topline results expected in the third quarter of 2024 Completed two underwritten public offerings in 2024; Cash and investments of $451.2 million as of April 30, 2024 extends runway into 2027 BOSTON, May 13, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX),...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the first quarter of 2024 as well as an update to the business. “It’s a very exciting time for Fulcrum as we remain...

Abacus Life Reports First Quarter 2024 Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

– First Quarter 2024 Total Revenue More Than Doubled Year-over-Year to $21.5 Million – – Driven by 59% Year-over-Year Growth in Direct-to-Consumer Division – ORLANDO, Fla., May 13, 2024 (GLOBE NEWSWIRE) — Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today reported results for the first quarter ended March 31, 2024. “We are pleased with our continued momentum, delivering yet another strong quarterly performance due to our relentless execution, and further validating the resiliency and profitability of our business model,” said Jay Jackson, Chief Executive Officer of Abacus. “In addition to our strong growth, we launched our technology subdivision ABL Tech, raised an additional $25 million from the issuance...

The Keg Royalties Income Fund announces May 2024 cash distribution

Written by Customer Service on May 13, 2024. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its May 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at May 21, 2024. The May 2024 distribution will be paid on May 31, 2024. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system sales exceeding $700 million,...

Auction result of Treasury Bills – RIKV 24 0717 – RIKV 24 1120

Written by Customer Service on May 13, 2024. Posted in Public Companies.

Series RIKV 24 0717 RIKV 24 1120 Settlement Date 05/15/2024 05/15/2024 Total Amount Allocated (MM) 23,950 27,000 All Bids Awarded At (Price / Simple interest) 98.382 / 9.398 95.273 / 9.451 Total Number of Bids Received 18 23 Total Amount of All Bids Received (MM) 34,590 49,691 Total Number of Successful Bids 11 15 Number of Bids Allocated in Full 11 13 Lowest Price / Highest Simple Interest Allocated 98.382 / 9.398 95.273 / 9.451 Highest Price / Lowest Simple Interest Allocated 98.434 / 9.091 95.374 / 9.239 Lowest Price / Highest Simple Interest Allocated in Full 98.382 / 9.398 95.274 / 9.448 Weighted Average of Successful Bids (Price/Simple Interest) 98.390 / 9.351 95.298 / 9.398 Best Bid (Price / Simple Interest) 98.434 / 9.091 95.374 / 9.239 Worst Bid (Price / Simple Interest) 98.280 / 10.001 95.202 / 9.600 Weighted...

CLM Announces Management and Board Changes

Written by Customer Service on May 13, 2024. Posted in Public Companies.

Brett Lynch to become Executive Chairman & Richard Quesnel to become President & Chief Executive Officer TORONTO, May 13, 2024 (GLOBE NEWSWIRE) — Consolidated Lithium Metals Inc. (TSXV: CLM | OTCQB: JORFF | FRA: Z36) (“CLM” or the “Company“) is pleased to announce the appointment of Brett Lynch as Executive Chairman, Richard Quesnel as President and Chief Executive Officer, and Rene Bharti as Vice President of Corporate Development, each effective immediately. Brett Lynch appointed as Executive Chairman Mr. Lynch stated, “having been a director on the board of CLM for several years, I am excited to further deepen my role and responsibilities in CLM as Executive Chairman. I believe that CLM is ideally placed to become a significant player in the development of Quebec’s lithium supply chain. I anticipate that our experience...

Titan Medical Reports Financial Results for the First Quarter 2024

Written by Customer Service on May 13, 2024. Posted in Public Companies.

TORONTO, Ontario, May 13, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three months ended March 31, 2024. Recent Activities: On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement (the “Definitive Agreement”) with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction (the “Transaction”). Under the terms of the Definitive Agreement, a newly incorporated and wholly-owned subsidiary of the Company and Conavi will amalgamate and the shareholders of Conavi will be issued Common Shares of the Company (“Common Shares”) based on an exchange ratio to be determined pursuant to the Definitive Agreement. The exchange ratio will be adjusted, if necessary, such that the Company’s shareholders...

Day: May 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice